Anthera Pharmaceuticals (NASDAQ:ANTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The firm currently has a $1.75 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 17.45% from the company’s previous close.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
A number of other equities analysts also recently commented on the company. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.32. During the same period in the prior year, the company posted ($4.85) EPS. sell-side analysts anticipate that Anthera Pharmaceuticals will post -3.09 EPS for the current fiscal year.
An institutional investor recently raised its position in Anthera Pharmaceuticals stock. Wedbush Securities Inc. boosted its position in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 75.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,764 shares of the biopharmaceutical company’s stock after purchasing an additional 31,800 shares during the quarter. Wedbush Securities Inc. owned approximately 0.68% of Anthera Pharmaceuticals worth $106,000 at the end of the most recent quarter. 16.10% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/08/anthera-pharmaceuticals-anth-raised-to-buy-at-zacks-investment-research.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.